A "not medically necessary" denial is one of the most frustrating letters to receive. It sounds like a judgment about your own health. Usually it is a plan's internal criteria not being satisfied on paper.
Find out the exact criteria your plan uses, then decide whether to appeal. telos rx offers compounded semaglutide and tirzepatide through an asynchronous intake reviewed by a licensed provider, evaluated on medical grounds rather than a plan's internal medical necessity checklist.
Start your intake →What "not medically necessary" actually means
Insurance plans define medical necessity using their own internal policy documents, not a universal medical standard shared across every insurer in the country.
A denial under this label usually means your documented file did not meet the plan's specific criteria. Things like a minimum body mass index, documented comorbidities, or proof other treatments were tried first all matter.
It does not mean a reviewing physician looked at your case and concluded GLP-1 therapy would not help you. Many of these reviews are conducted by staff following a checklist rather than a treating physician.
Plans update their medical necessity criteria periodically, sometimes making them stricter for GLP-1 medications specifically as demand and cost have grown across the industry in recent years.
This shifting bar can feel unfair when you were approved once and then denied later for what looks like the exact same clinical picture. It reflects the plan's changing internal policy, not any real change in you.
Your denial letter should cite the specific policy or criteria used. If it does not, request that information directly, since it is central to building any kind of effective response.
Some plans update their medical necessity criteria without prominently notifying members. It is worth confirming you are looking at the current version of the policy rather than an outdated copy found online.
How to challenge this kind of denial
Start by getting the plan's actual medical necessity policy for GLP-1 medications in writing. This document lists precisely what your file needs to contain, and comparing it against what was submitted often reveals the gap.
Some plans make this document hard to find on their public website. Calling member services and asking for it by name, along with a reference number for the request, tends to work better than searching alone.
Ask your provider to write a detailed letter of medical necessity addressing each criterion specifically, rather than a general statement of support. Specificity matters far more than enthusiasm in this kind of appeal.
Include objective documentation wherever possible: labs, prior treatment records, and notes about any comorbid conditions that support the case for treatment under the plan's own stated criteria.
A well-organized appeal file, with each criterion addressed in the same order the policy lists it, makes a reviewer's job easier and can shorten the time it takes to reach a decision.
A peer-to-peer review can be especially effective here, since it lets your physician speak directly to the reviewing clinician. That conversation can address why your case meets medical necessity in terms the reviewer's own policy recognizes.
If the plan's policy itself seems unreasonably strict compared to typical clinical practice, that is worth raising in a formal appeal. On its own, it rarely overturns a denial without other supporting documentation.
While you build your appeal, some people also explore a cash-pay intake so treatment is not entirely dependent on how one specific appeal turns out.
Filing the formal appeal
Most plans give a window measured in months to file an internal appeal, with the exact deadline printed on your denial letter. Missing it closes off that particular route.
The internal appeal should directly address each element of the plan's medical necessity criteria, supported by your provider's documentation and any relevant records from your file.
If the internal appeal is also denied, many states allow an external review by an independent party outside your insurance company, since plans do not have unchecked authority over medical necessity determinations.
These appeals take real time, often several weeks from filing to resolution. Even a well-documented case has no certain outcome at the end of the process.
Keep a complete record of everything submitted and every conversation held. If your plan later claims something was missing, your own documentation lets you respond with specifics rather than memory alone.
If your employer has a benefits advocate or HR liaison, ask whether they can assist. Some larger employers have staff who regularly help employees navigate exactly this kind of insurance appeal.
Key takeaway: A medical necessity denial reflects a plan's paperwork criteria, not a verdict on your health. Get the specific policy, address it directly, and consider a cash-pay path in parallel.
What this denial does not close off
A medical necessity denial does not mean GLP-1 therapy is inappropriate for you as a person. It means your documented file did not satisfy one specific insurer's internal checklist at this point in time.
It also does not mean your only path forward is a lengthy appeal with an uncertain outcome. A cash-pay compounded option exists specifically for people in this situation, evaluated on its own medical terms.
This does not change what insurance actually pays for. Medicare, Medicaid, and commercial plans do not cover compounded medication, regardless of how a branded prescription's medical necessity denial is eventually resolved.
What is available, regardless of your plan's internal criteria, is a compounded GLP-1 option evaluated by a licensed provider based on your actual history rather than a checklist built for cost control.
That evaluation is genuinely individualized. Two people with similar denial letters could receive quite different recommendations from a telos rx provider, depending on the full picture of their specific health history and goals.
Comparing the real monthly cost of a cash-pay compounded plan against the uncertain timeline of an appeal is worth doing honestly before committing fully to either path.
Delayed care has its own cost too, even when it does not show up on a bill. Weeks spent waiting on an appeal outcome are weeks without treatment, and that has real weight in the decision.
The compounded path telos rx offers
telos rx offers compounded semaglutide and compounded tirzepatide, prepared by partner compounding pharmacies in the United States under an individualized provider plan.
The intake is asynchronous. You complete a health history on your own schedule, and a provider reviews it based on your actual case rather than a plan's predetermined checklist of qualifying criteria.
Approval is a genuine medical decision. A provider can decline treatment if your history does not support it, and that possibility exists for every applicant, not only those previously denied by insurance.
If a provider has questions about anything in your intake, they message you directly through the platform rather than requiring a phone call, and you can respond whenever it works for you.
Pricing starts as low as $99 a month for semaglutide, and most telos rx plans qualify for FSA or HSA funds if you have access to either account type.
You can start your intake here whether your appeal is still in progress or you have decided not to pursue one at all.
Shipping is included, and orders typically arrive within a couple of days once a provider approves your plan, which can matter if a long appeal has already delayed treatment longer than expected.
Weighing your options
Some people pursue both an appeal and a cash-pay intake at the same time, treating them as parallel paths rather than a sequential process with one clear next step.
Others decide the appeal's uncertain timeline is not worth the wait, especially when a cash-pay option is available at a predictable, upfront price without any internal criteria to satisfy.
There is no wrong choice here as long as it is an informed one. Understanding both paths clearly, including their real timelines and costs, is what makes the decision genuinely yours rather than one made by default.
If you prefer a different starting approach, telos rx also offers microdosed tirzepatide and an oral option through the oral GLP-1 program for those who would rather avoid injections.
Your provider makes the final call on which option, if any, fits your history. None of these options require you to have already won an insurance appeal first.
If your plan does eventually approve the branded medication after a successful appeal, you are free to switch, and nothing about trying a compounded option in the meantime affects that outcome.
Discuss any switch with your provider first rather than making the change entirely on your own. They can help you think through timing and what a careful transition between options should look like for your specific plan and history.
Frequently Asked Questions
Does "not medically necessary" mean my doctor was wrong to prescribe it?
No. It typically means your documented file did not satisfy the plan's specific internal criteria, which are set by the insurer, not by clinical medical judgment alone.
Can I get the exact medical necessity criteria my plan uses?
Yes. You are generally entitled to request this in writing. It lists precisely what documentation your case needs to include for approval under that plan's specific policy.
How long does an appeal of this kind of denial take?
It varies by plan, but weeks rather than days is typical. A peer-to-peer review can sometimes resolve it faster than a full written appeal.
Does telos rx use the same medical necessity criteria as insurers?
No. telos rx is a cash-pay service. A licensed provider evaluates your history directly rather than applying an insurer's specific internal checklist.
Is compounded GLP-1 medication covered by insurance?
No. Compounded medication is not covered by insurance, Medicare, or Medicaid. telos rx operates entirely as a cash-pay service, with pricing shown upfront.
What if my provider does not approve my intake?
You pay nothing if declined. Approval depends on your individual health history, and a provider may explain why the medication does not fit your specific situation.
telos rx is LegitScript-certified. Compounded semaglutide and tirzepatide are not FDA-approved, and they are prepared by partner compounding pharmacies in the United States. This article is general information, not medical advice, and does not replace guidance from your own provider or insurer. Care is subject to medical approval by a licensed provider, and approval is not automatic. telos rx operates as an online-first, asynchronous telehealth service, and compounded medication is not covered by insurance, Medicare, or Medicaid.
For background on prescription medications used for weight management, see the NIH overview of weight-loss medications. For how compounded drugs are regulated in the United States, see the FDA overview of drug compounding.
Ready to explore a cash-pay option? Begin your GLP-1 intake or learn more on the telos rx semaglutide page.